Advertisement

Topics

Lampalizumab reduces geographic atrophy lesion progression

14:06 EDT 21 Jun 2017 | Healio

Monthly lampalizumab, a potential therapy for patients with geographic atrophy secondary to age-related macular degeneration, reduced lesion area progression by 20% compared to a sham control, according to results of the MAHALO study. The phase 2 clinical trial, a multicenter, randomized controlled study, included patients with geographic atrophy secondary to age-related macular degeneration randomized into three treatment groups: 42 patients receiving 10 mg intravitreal injections of lampalizumab every month, 41 patients receiving injections every other month and 40 patients in a sham control group.

Original Article: Lampalizumab reduces geographic atrophy lesion progression

NEXT ARTICLE

More From BioPortfolio on "Lampalizumab reduces geographic atrophy lesion progression"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...